September 14, 2014
1 min read

Quantel earns CE mark for Vitra PDT platform

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

LONDON —Quantel Medical has received CE mark approval for its Vitra photodynamic therapy laser platform, according to a company press release.

The platform is indicated for the treatment of polypoidal choroidal vasculopathy and central serous retinopathy.

“Quantel is currently the sole provider of a laser approved to treat these two very serious retinal conditions,” Jean-Marc Gendre, CEO of Quantel Medical, said in the press release. “This comes at an opportune moment, as demand for PDT treatment technologies is expected to increase as the disease’s true prevalence is realized. We’re confident that our world-class laser technology will provide ophthalmologists a quality, cost-effective solution, and are excited to begin commercialization in Europe and Asia.”

The laser platform will be commercialized immediately in countries requiring CE registration, according to the press release.